Identification

Name
Proparacaine
Accession Number
DB00807  (APRD00522)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Proparacaine is a topical anesthetic drug of the amino ester group. It is available as its hydrochloride salt in ophthalmic solutions at a concentration of 0.5%.

Structure
Thumb
Synonyms
  • Proximetacaina
  • Proxymetacaine
  • Proxymetacainum
Product Ingredients
IngredientUNIICASInChI Key
Proparacaine hydrochlorideU96OL57GOY5875-06-9BFUUJUGQJUTPAF-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlcaineSolution / drops0.5 %OphthalmicNovartis1971-12-31Not applicableCanada
OphtheticSolution / drops.5 %OphthalmicAllergan1964-12-312011-08-04Canada
ProparacaineLiquid0.5 %Ophthalmic; TopicalEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
R.O.-parcaine Dps 5mg/mlSolution / drops5 mgOphthalmicRichmond Pharmaceuticals1993-12-311997-08-11Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlcaineSolution / drops5 mg/mLOphthalmicAlcon, Inc.1973-10-19Not applicableUs
Odan-proparacaineSolution.5 %Ophthalmic; TopicalOdan Laboratories Ltd1985-12-31Not applicableCanada
PMS-proparacaine Hydrochloride Oph Soltn 0.5%Solution / drops.5 %OphthalmicPharmascience Inc1992-12-311996-09-10Canada
Proparacaine HydrochlorideSolution / drops5 mg/mLOphthalmicH.J. Harkins Company1995-09-29Not applicableUs
Proparacaine HydrochlorideSolution / drops5 mg/mLOphthalmicRemedy Repack2016-07-292017-03-09Us
Proparacaine HydrochlorideSolution / drops5 mg/mLOphthalmicNu Care Pharmaceuticals,inc.1995-09-29Not applicableUs
Proparacaine HydrochlorideSolution / drops5 mg/mLOphthalmicBauch & Lomb Incorporated1995-09-29Not applicableUs
Proparacaine HydrochlorideSolution5 mg/mLOphthalmicStat Rx USA2000-06-052018-02-08Us
Proparacaine HydrochlorideSolution / drops5 mg/mLOphthalmicA S Medication Solutions2000-06-052017-06-20Us
Proparacaine HydrochlorideSolution5 mg/mLOphthalmicRebel Distributors1995-09-29Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Odan-fluoracaineProparacaine hydrochloride (0.5 %) + Fluorescein sodium (0.25 %)SolutionOphthalmicOdan Laboratories Ltd1986-12-31Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FlucaineProparacaine hydrochloride (5 mg/mL) + Fluorescein sodium (2.5 mg/mL)Solution / dropsOphthalmicO Cu Soft, Inc.1989-03-30Not applicableUs
Fluorescein Sodium and Proparacaine HydrochlorideProparacaine hydrochloride (5 mg/mL) + Fluorescein sodium (2.5 mg/mL)Solution / dropsOphthalmicAltaire Pharmaceuticals Inc.2000-06-14Not applicableUs
Mydriatic-4Proparacaine hydrochloride (5 mg/mL) + Ketorolac tromethamine (5 mg/mL) + Phenylephrine hydrochloride (25 mg/mL) + Tropicamide (10 mg/mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-05-01Not applicableUs
International/Other Brands
Ak-Taine / Diocaine / Ocu-Caine / Ophthaine / Ophthetic / Spectro-Caine
Categories
UNII
B4OB0JHI1X
CAS number
499-67-2
Weight
Average: 294.3892
Monoisotopic: 294.194342708
Chemical Formula
C16H26N2O3
InChI Key
KCLANYCVBBTKTO-UHFFFAOYSA-N
InChI
InChI=1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3
IUPAC Name
2-(diethylamino)ethyl 3-amino-4-propoxybenzoate
SMILES
CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC

Pharmacology

Indication

Used as a local (ophthalmic) anesthetic.

Associated Therapies
Pharmacodynamics

Proparacaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. More specifically, proparacaine appears to bind or antagonize the function of voltage gated sodium channels.

Mechanism of action

The exact mechanism whereby proparacaine and other local anesthetics influence the permeability of the cell membrane is unknown; however, several studies indicate that local anesthetics may limit sodium ion permeability through the lipid layer of the nerve cell membrane. Proparacaine may alter epithelial sodium channels through interaction with channel protein residues. This limitation prevents the fundamental change necessary for the generation of the action potential.

TargetActionsOrganism
ASodium channel protein type 10 subunit alpha
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Plasma

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Proparacaine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Proparacaine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Proparacaine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Proparacaine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Proparacaine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Proparacaine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Proparacaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Proparacaine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Proparacaine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Proparacaine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Azaperone.Investigational, Vet Approved
AzelastineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Proparacaine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Benperidol.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Proparacaine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Proparacaine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Bromperidol.Approved, Investigational
BrotizolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Proparacaine.Approved, Investigational
BuprenorphineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Proparacaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Proparacaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Proparacaine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Proparacaine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Proparacaine is combined with Canertinib.Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Proparacaine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Proparacaine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Proparacaine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Proparacaine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chloroprocaine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Proparacaine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Proparacaine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Proparacaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Proparacaine is combined with Citalopram.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Proparacaine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Proparacaine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Proparacaine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Proparacaine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Proparacaine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Proparacaine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Proparacaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Proparacaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cocaine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Proparacaine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Proparacaine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Proparacaine.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Proparacaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Proparacaine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Proparacaine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Proparacaine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Proparacaine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Proparacaine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Proparacaine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Proparacaine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Proparacaine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Proparacaine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Proparacaine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Proparacaine.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when Proparacaine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Proparacaine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Proparacaine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Proparacaine.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Proparacaine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Proparacaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Proparacaine.Approved, Investigational
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proparacaine.Approved, Illicit, Withdrawn
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Proparacaine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etizolam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Proparacaine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Proparacaine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Proparacaine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fludiazepam.Approved, Illicit
FlunitrazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flunitrazepam.Approved, Illicit
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Proparacaine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Proparacaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Proparacaine.Approved, Illicit, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Proparacaine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fospropofol.Approved, Illicit, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Proparacaine.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Proparacaine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Proparacaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Glutethimide.Approved, Illicit
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Proparacaine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Proparacaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Proparacaine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Proparacaine.Approved, Illicit
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Proparacaine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Proparacaine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Proparacaine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Proparacaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Proparacaine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketobemidone.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Proparacaine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Proparacaine.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Proparacaine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Loprazolam.Experimental
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Proparacaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Proparacaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Proparacaine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Proparacaine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mebicar.Experimental
MedazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Proparacaine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Proparacaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Proparacaine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Proparacaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Proparacaine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Proparacaine.Approved
MethotrimeprazineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methylphenobarbital.Approved
MetyrosineProparacaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Proparacaine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Proparacaine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Investigational
MirtazapineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Proparacaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Proparacaine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Proparacaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Proparacaine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Proparacaine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Proparacaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Proparacaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Proparacaine is combined with Opium.Approved, Illicit
OrphenadrineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Proparacaine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Proparacaine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxybuprocaine.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Proparacaine.Approved
ParaldehydeProparacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Proparacaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Proparacaine.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Proparacaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Proparacaine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenibut.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Proparacaine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Proparacaine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Proparacaine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Proparacaine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Proparacaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Prazepam.Approved, Illicit
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Proparacaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Proparacaine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Proparacaine.Approved, Investigational, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Proparacaine.Approved, Vet Approved
PropanididThe risk or severity of adverse effects can be increased when Proparacaine is combined with Propanidid.Experimental
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Proparacaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Proparacaine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Proparacaine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Proparacaine.Approved, Illicit
QuinisocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Proparacaine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Proparacaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Proparacaine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Proparacaine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Proparacaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Romifidine.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Proparacaine.Approved
RotigotineProparacaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Proparacaine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Proparacaine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Proparacaine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Proparacaine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Proparacaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proparacaine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sultopride.Experimental
SuvorexantProparacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Proparacaine.Approved, Investigational
Technetium Tc-99m tilmanoceptProparacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Proparacaine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Proparacaine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetrodotoxin.Investigational
ThalidomideProparacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Proparacaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Proparacaine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Proparacaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Proparacaine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Proparacaine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Proparacaine.Approved, Withdrawn
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Proparacaine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Proparacaine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Proparacaine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Proparacaine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Proparacaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Proparacaine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Proparacaine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Proparacaine.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Proparacaine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Proparacaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Proparacaine.Approved, Illicit, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Proparacaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zolazepam.Vet Approved
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Proparacaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Proparacaine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014945
KEGG Drug
D08448
KEGG Compound
C07383
PubChem Compound
4935
PubChem Substance
46507960
ChemSpider
4766
BindingDB
50017718
ChEBI
8485
ChEMBL
CHEMBL1196
Therapeutic Targets Database
DAP000513
PharmGKB
PA164776849
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Proparacaine
ATC Codes
S01HA04 — Proxymetacaine
AHFS Codes
  • 52:16.00 — Local Anesthetics
FDA label
Download (118 KB)
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentPain1
Not AvailableCompletedDiagnosticPostoperative pain / Postoperative; Parotitis / Prophylaxis against postoperative nausea and vomiting / Vitreoretinal Surgery1
Not AvailableCompletedSupportive CareAnaesthesia therapy / Cataract Unilateral Pending Extraction1
Not AvailableCompletedTreatmentCataracts2
Not AvailableRecruitingOtherAge-Related Macular Degeneration (ARMD) / Diabetic Macular Edema (DME) / Injection Site / Injection site infection / Postoperative pain1
Not AvailableRecruitingTreatmentGlaucoma, Angle-Closure1
Not AvailableRecruitingTreatmentMyopia / Refractive Errors1
Not AvailableRecruitingTreatmentPerioperative Pain Experiences1
Not AvailableTerminatedSupportive CarePain / Retinopathy of Prematurity1
Not AvailableUnknown StatusTreatmentMacular Degeneration1

Pharmacoeconomics

Manufacturers
  • Alcon laboratories inc
  • Pharmafair inc
  • Apothecon inc div bristol myers squibb
  • Allergan pharmaceutical
  • Optopics laboratories corp
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Taylor pharmacal co
Packagers
  • Accutome Inc.
  • Akorn Inc.
  • Alcon Laboratories
  • Allergan Inc.
  • Altaire Pharmaceuticals
  • A-S Medication Solutions LLC
  • Bausch & Lomb Inc.
  • Conta Care Ophthalmics and Diagnostics
  • Deca Pharmaceuticals LLC
  • Diversified Healthcare Services Inc.
  • Eye Care and Cure Corp.
  • Eye Supply Usa Inc.
  • Falcon Pharmaceuticals Ltd.
  • Medical Ophthalmics
  • MWI Veterinary Supply Co.
  • Ocusoft
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Professional Co.
  • Rx Veterinary Products
  • Stat Rx Usa
  • Wa Butler Co.
  • Wilson Ophthalmic Corp.
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic0.5 %
Solution / dropsOphthalmic
SolutionOphthalmic
SolutionOphthalmic; Topical.5 %
Solution / dropsOphthalmic.5 %
LiquidOphthalmic; Topical0.5 %
SolutionOphthalmic5 mg/mL
Solution / dropsOphthalmic5 mg/mL
Solution / dropsOphthalmic5 mg
Prices
Unit descriptionCostUnit
Proparacaine hcl powder84.0USD g
Proparacaine HCl 0.5% Solution 15ml Bottle14.99USD bottle
Alcaine 0.5% eye drops2.19USD ml
Proparacaine 0.5% eye drops1.27USD ml
Ophthetic 0.5% eye drops1.02USD ml
Alcaine 0.5 % Solution0.68USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)182-183.3 °CNot Available
water solubilitySolubleNot Available
logP2.5Not Available
pKa3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.39 mg/mLALOGPS
logP2.97ALOGPS
logP2.6ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.79 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity86.04 m3·mol-1ChemAxon
Polarizability34 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9769
Blood Brain Barrier+0.8876
Caco-2 permeable+0.6501
P-glycoprotein substrateSubstrate0.7085
P-glycoprotein inhibitor INon-inhibitor0.7586
P-glycoprotein inhibitor IINon-inhibitor0.9645
Renal organic cation transporterNon-inhibitor0.7172
CYP450 2C9 substrateNon-substrate0.8202
CYP450 2D6 substrateNon-substrate0.5953
CYP450 3A4 substrateSubstrate0.5624
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9093
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5247
Ames testNon AMES toxic0.7542
CarcinogenicityNon-carcinogens0.7336
BiodegradationNot ready biodegradable0.9764
Rat acute toxicity2.5543 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8356
hERG inhibition (predictor II)Non-inhibitor0.5406
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f6t-0590000000-0aae7080739b3c83b4a4

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Aminobenzoic acids and derivatives / Aminophenyl ethers / Phenoxy compounds / Benzoyl derivatives / Aniline and substituted anilines / Alkyl aryl ethers / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives
show 4 more
Substituents
Aminobenzoic acid or derivatives / Benzoate ester / Aminophenyl ether / Phenoxy compound / Benzoyl / Aniline or substituted anilines / Phenol ether / Alkyl aryl ether / Amino acid or derivatives / Tertiary aliphatic amine
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
benzoate ester (CHEBI:8485)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
Gene Name
SCN10A
Uniprot ID
Q9Y5Y9
Uniprot Name
Sodium channel protein type 10 subunit alpha
Molecular Weight
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:45